The DOI matches its Crossref record.
Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects.
Open accessAbstract
The hemodynamic effects of intravenous verapamil administration were examined in 27 patients with hypertrophic cardiomyopathy. Increasing doses of verapamil produced small increases in heart rate and cardiac output and a significant decrease in systolic blood pressure, but had no significance effect on mean pulmonary artery wedge pressure or left ventricular end-diastolic pressure. The highest dose of verapamil increased heart rate from 72 +/- 3 to 81 +/- 6 beats/min and reduced systolic blood pressure from 118 +/- 8 to 99 +/- 5 mm Hg (p less than 0.005). This dose decreased the basal left ventricular outflow tract gradient from 94 +/- 14 to 49 +/- 14 mm Hg and the average left ventricular outflow tract gradient during the Valsalva maneuver from 76 +/- 5 to 63 +/- 13 mm Hg, during amyl nitrite inhalation from 69 +/- 15 to 39 +/- 13 mm Hg, and during isoproterenol infusion from 108 +/- 29 to 70 +/- 21 mm Hg (p less than 0.01). These results indicate that verapamil can significantly decrease left ventricular outflow obstruction in patients with hypertrophic cardiomyopathy and thus may provide an important new therapeutic agent in the treatment of this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318223e2bd · Cited by 2,104
Self-citation2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.011 · Cited by 1,276
Self-citationComparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem
Henry, P. D. (1980) · The American Journal of Cardiology · doi:10.1016/0002-9149(80)90366-5 · Cited by 843
Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review
Wigle, E. D., Sasson, Z., Henderson, M. A., Ruddy, T. D., Fulop, J., Rakowski, H., & Williams, W. G. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(85)90024-6 · Cited by 823
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318223e230 · Cited by 818
Self-citationHypertrophic Cardiomyopathy: Clinical Spectrum and Treatment
Wigle, E. D., Rakowski, H., Kimball, B. P., & Williams, W. G. (1995) · Circulation · doi:10.1161/01.cir.92.7.1680 · Cited by 778
STONE, P. H., ANTMAN, E. M., MULLER, J. E., & BRAUNWALD, E. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-886 · Cited by 540
Bonow, R. O., Rosing, D. R., Bacharach, S. L., Green, M. V., Kent, K. M., Lipson, L. C., Maron, B. J., Leon, M. B., & Epstein, S. E. (1981) · Circulation · doi:10.1161/01.cir.64.4.787 · Cited by 393
Self-citationMaron, B. J., Bonow, R. O., Cannon, R. O., Leon, M. B., & Epstein, S. E. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704023161405 · Cited by 370
Self-citationSetaro, J. F., Zaret, B. L., Schulman, D. S., Black, H. R., & Soufer, R. (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)90937-v · Cited by 350
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., Mahrholdt, H., et al. (2014) · Kardiologia Polska · doi:10.5603/kp.2014.0212 · Cited by 341
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2011.10.020 · Cited by 322
Self-citationGersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.10.825 · Cited by 279
Self-citationEpstein, S. E., & Rosing, D. R. (1981) · Circulation · doi:10.1161/01.cir.64.3.437 · Cited by 271
Self-citationKawai, C., Konishi, T., Matsuyama, E., & Okazaki, H. (1981) · Circulation · doi:10.1161/01.cir.63.5.1035 · Cited by 254
Metadata
- Authors
- Rosing, D. R., Kent, K. M., Borer, J. S., Seides, S. F., Maron, B. J., & Epstein, S. E.
- Venue
- Circulation
- Published
- 1979-12
- Volume
- 60
- Issue
- 6
- Pages
- 1201-1207
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2094932823
- Cited by
- 230
- References
- 0
- FWCI
- 20.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.